Nano-X Imaging Q3 revenue grows on AI solutions; flags going concern issues

By Reuters News


Overview

  • Israel medical imaging tech firm's preliminary Q3 revenue rose yr/yr

  • Company's AI and software solutions revenue grew, driven by consolidation of Nanox Health IT Inc.

  • Company warns cash levels raise substantial doubt about ability to continue as a going concern


Outlook

  • Company expects cash and deposits as of Sept 30, 2026, are not sufficient for one year

  • Company expects to continue to incur significant costs related to ongoing operations

  • Company may delay, reduce or eliminate product development if unable to raise additional funds


Result Drivers

  • AI AND SOFTWARE SOLUTIONS - Revenue growth driven mainly by consolidation of Nanox Health IT Inc.

  • IMAGING SYSTEM SALES - Higher imaging system and OEM services revenue attributed to additional Nanox.ARC CapEx agreement

  • TELERADIOLOGY SERVICES - Teleradiology revenue remained flat yr/yr at $3.1 mln


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$4.3-$4.4 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Nano-X Imaging Ltd is $4.40, about 795.9% above its October 15 closing price of $0.49


Reuters Recommended Reads

  • Oct 15 - CoreWeave's slump spotlights growing burden of debt behind AI boom

  • Oct 15 - France's Pernod Ricard Q1 sales fall marginally, flags weakness in US and China markets


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.